Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
US antibody-drug conjugate (ADC) specialist ImmunoGen (Nasdaq: IMGN) today announced findings from two subset analyses of the Phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx). 28 September 2023
Having been collaborating for a decade, US RNA-targeted drug developer Ionis Pharmaceuticals and Swiss pharm giant Roche have signed a new agreement. 28 September 2023
Shares of US biotech Gritstone bio leapt almost 31% to $1.57 in pre-market trading on the news it had been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). 28 September 2023
Seattle, USA-based clinical-stage biopharma Avalyn Pharmaceuticals has announced the closing of an oversubscribed $175 million Series C financing. 28 September 2023
CRISPR genome-editing biopharma company Caribou Biosciences (Nasdaq: CRBU) dipped 3% to $4.76, after it revealed it has received notice from a unit of AbbVie (NYSE: ABBV) revealing that the US pharma major has elected to terminate the collaboration and license agreement, first signed in February 2021. 27 September 2023
Adding to recent big-bucks deals with Merck & Co and Boehringer Ingelheim, Ginkgo Bioworks has now signed a collaboration deal with US pharma giant Pfizer focused on the discovery of RNA-based drug candidates. 27 September 2023
Swedish biotech Biosergen saw its shares close down 14.4% at 1.37 kronor yesterday after it revealed a co-development and licensing deal with Indian drugmaker Alkem Laboratories for BSG005, an innovative polyene macrolide, through Phase II and phase III trials for sale in the Indian market. 27 September 2023
USA-based Ionis Pharmaceuticals yesterday released positive top-line results for the Phase III Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a rare genetic disorder. 27 September 2023
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Coherus BioSciences’ application for Udenyca Onbody, the company's on-body injector (OBI) form of Udenyca (pegfilgrastim-cbqv). 26 September 2023
California, USA-based biotech AcuraStem has entered into a license agreement with Japan’s largest pharma company Takeda to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of amyotrophic lateral sclerosis (ALS). 26 September 2023
A $250 million private financing for California’s BridgeBio Pharma will support a possible launch of acoramidis, as well as further late-stage pipeline development. 26 September 2023
Australian dermatology company Botanix today revealed it has received a communication from the US Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) submission for sofpironium bromide (SB) gel, 15%. 26 September 2023
Ahead of an advisory panel meeting of the US Food and Drug Administration’s scientists, the agency’s briefing notes paint a pessimistic picture for the amyotrophic lateral sclerosis (ALS) candidate NurOwn (autologous MSC-NTF cells). 26 September 2023
Danish company Acesion Pharma has closed an oversubscribed Series B financing round, raising around 43 million euros ($48 million) to support its work in atrial fibrillation (AF). 26 September 2023
Two Chinese contract development and manufacturing organizations (CDMO) with significant US operations have agreed to collaborate in the growth area of mRNA manufacturing. 25 September 2023
Continuing its recent strong investment in the area of oncology, French privately-held company Pierre Fabre has inked a new drug discovery deal with British firm Vernalis. 25 September 2023
French biopharma company Inventiva saw its US traded shares jump 11.1% to $4.19 yesterday, after it announced a deal with Japan-based Hepalys Pharma, a company incubated by Catalys Pacific. 22 September 2023